Drug facts
MoleculeRivaroxaban (Xarelto)
Generics already compete: 20 makers on the market. 62 A-rated products from 19 makers substitute at the counter.
Xarelto was first approved by the FDA on 07/01/2011 under NDA 022406; the application holder is Janssen Pharmaceuticals Inc.
The latest NADAC for RIVAROXABAN 2.5 MG TABLET is $0.63 per unit (as of 10/28/2026).
Holder Janssen Pharmaceuticals IncApplication NDA 022406Approved 07/01/2011
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
2,847days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved07/01/2011
Last patent08/17/2034
2012201620202024202820322036
- Latest patent
- 08/17/2034Xarelto Orange Book
02Competition
- Generics
- 20 generic makers Orange Book
- Staged generics
- 2 passed FDA review, awaiting market entry FDA
- First generic approved
- 03/03/2025 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Rivaroxaban profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.63 per unitRIVAROXABAN 2.5 MG TABLET, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Janssen Pharmaceuticals Inc Orange Book
- Application
- NDA 022406 Orange Book
- First approved
- 07/01/2011 Orange Book
- Dosage forms
- for suspension; tablet
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.